tiprankstipranks
Trending News
More News >
Abivax SA (FR:ABVX)
:ABVX
Advertisement

Abivax SA (ABVX) AI Stock Analysis

Compare
25 Followers

Top Page

FR:ABVX

Abivax SA

(LSE:ABVX)

Select Model
Select Model
Select Model
Neutral 58 (OpenAI - 4o)
Rating:58Neutral
Price Target:
€67.00
▼(-4.69% Downside)
Abivax SA's overall stock score of 58 reflects its strong revenue growth and liquidity position offset by significant profitability challenges and a highly leveraged balance sheet. Technical indicators suggest robust price momentum, though the valuation is constrained by negative earnings.

Abivax SA (ABVX) vs. iShares MSCI France ETF (EWQ)

Abivax SA Business Overview & Revenue Model

Company DescriptionAbivax SA (ABVX) is a clinical-stage biotechnology company based in France, specializing in the development of innovative therapeutic solutions for inflammatory diseases and viral infections. The company focuses on advancing its proprietary drug candidates primarily in the areas of ulcerative colitis, Crohn's disease, and hepatitis B, leveraging its expertise in immunology and drug development to create impactful treatments that address unmet medical needs.
How the Company Makes MoneyAbivax generates revenue primarily through partnerships and collaborations with pharmaceutical companies and research institutions. The company may receive milestone payments and royalties from its partners upon achieving specific developmental or commercial targets for its drug candidates. Additionally, funding through grants and public offerings can contribute to its financial resources. As a clinical-stage company, its current revenue streams are limited, and it relies on external funding and partnerships to support its research and development activities.

Abivax SA Financial Statement Overview

Summary
Abivax SA shows significant revenue growth but struggles with profitability, having negative net income and operating cash flow. The balance sheet is highly leveraged, though the company maintains a strong cash position which supports liquidity.
Income Statement
35
Negative
Abivax SA has shown significant revenue growth from 2023 to 2024, but remains unprofitable with negative EBIT and net income. The company's gross profit margin is favorable, indicating effective cost control relative to revenue. However, the negative net profit margin highlights ongoing challenges in achieving profitability.
Balance Sheet
50
Neutral
The financial structure of Abivax SA is marked by a relatively high debt-to-equity ratio, indicating significant leverage which could pose risks. The equity ratio is low, reflecting limited shareholder equity relative to total assets. However, the company maintains a strong cash position, supporting liquidity.
Cash Flow
40
Negative
Abivax SA's cash flow from operations is negative, pointing to challenges in generating cash from its core activities. Free cash flow is also negative, but the company has maintained its liquidity through financing activities. The operating cash flow to net income ratio is unfavorable, indicating reliance on external funding.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue6.02M10.79M4.62M4.58M37.00K14.00K
Gross Profit6.02M10.79M4.49M4.51M-119.00K-52.00K
EBITDA-185.44M-167.68M-133.21M-53.31M-42.20M-37.74M
Net Income-195.39M-176.24M-147.74M-60.74M-42.45M-37.55M
Balance Sheet
Total Assets119.64M205.23M327.06M73.35M110.36M71.30M
Cash, Cash Equivalents and Short-Term Investments60.95M144.22M260.99M26.95M60.70M29.30M
Total Debt98.71M97.36M55.46M39.16M53.45M33.98M
Total Liabilities167.92M164.64M131.05M71.47M81.59M66.63M
Stockholders Equity-48.28M40.58M196.01M7.19M25.93M17.90M
Cash Flow
Free Cash Flow-137.42M-154.72M-97.39M-69.55M-47.30M-30.72M
Operating Cash Flow-136.96M-154.07M-97.13M-65.58M-45.66M-29.82M
Investing Cash Flow274.00K15.76M-8.10M-3.73M-1.46M-575.00K
Financing Cash Flow-23.98M28.21M335.29M32.21M82.68M49.93M

Abivax SA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price70.30
Price Trends
50DMA
62.10
Positive
100DMA
34.13
Positive
200DMA
20.22
Positive
Market Momentum
MACD
2.70
Positive
RSI
57.41
Neutral
STOCH
60.44
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ABVX, the sentiment is Positive. The current price of 70.3 is below the 20-day moving average (MA) of 71.25, above the 50-day MA of 62.10, and above the 200-day MA of 20.22, indicating a neutral trend. The MACD of 2.70 indicates Positive momentum. The RSI at 57.41 is Neutral, neither overbought nor oversold. The STOCH value of 60.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:ABVX.

Abivax SA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
€5.31B-148.98%18.52%
58
Neutral
725.39M-10.23-35.96%30.21%-76.83%
54
Neutral
156.18M-4.022.18%-45.41%-273.69%
50
Neutral
210.55M-1.50-20.97%
46
Neutral
701.83M-1.64172.73%-47.37%-26.56%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
FR:ABVX
Abivax SA
70.30
60.14
591.93%
GNFTF
Genfit
3.72
-2.33
-38.51%
IPHYF
Innate Pharma SA
2.00
-0.25
-11.11%
GB:0QAJ
DBV Technologies
1.56
0.83
113.70%
GB:0RNK
Inventiva
4.97
3.09
164.36%
GB:0OB3
Valneva
4.25
1.56
57.99%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Aug 01, 2025